Nordson (NDSN) Q2 2026 earnings review
Record Top-Line Driven by Broad Organic Growth; Guidance Raised
Nordson executed a remarkably clean quarter, delivering record Q2 sales of $741 million (+8.5% YoY) and record adjusted EPS of $2.86 (+18% YoY). Unlike many industrials struggling with uneven macro environments, Nordson saw organic growth across all three of its operating segments. A massive 18% YoY increase in backlog signals that the demand is real and forward-looking. This broad-based momentum gave management the confidence to raise full-year sales and earnings guidance. However, GAAP net income growth was muted (+4% YoY) due to significant non-cash pension and minority investment charges.
🐂 Bull Case
An 18% YoY increase in backlog entering Q3 virtually derisks the second half of the year and provides high visibility into the raised guidance.
The company demonstrated excellent operating leverage, turning an 8.5% sales increase into an 18% jump in adjusted EPS, with EBITDA margins holding strong at 32%.
🐻 Bear Case
Significant non-cash charges ($24M pension settlement, $10.4M minority investment loss) created a wide gap between GAAP EPS ($2.09) and Adjusted EPS ($2.86), lowering earnings quality.
While underlying organic growth in Medical and Fluid Solutions is strong (+8%), reported segment revenue grew only 5% due to the ongoing 4% headwind from the divested contract manufacturing business.
⚖️ Verdict: 🟢
Bullish. The combination of accelerating organic growth across all segments, record EBITDA, and an 18% backlog increase paints a picture of a company firing on all cylinders despite a complex industrial macro environment.
Key Themes
ATS Riding the Semiconductor & AI Cycle
The Advanced Technology Solutions (ATS) segment is accelerating, driven by robust demand for electronics dispense systems critical to advanced semiconductor packaging. Segment sales grew 10.1% YoY (8.5% organic). More impressively, operating leverage is kicking in: ATS EBITDA surged 22% YoY, pushing segment EBITDA margins to 27.2% (up from 24.5% a year ago). This confirms Nordson's strategic positioning within the AI hardware supply chain is paying off.
Surging Backlog Provides Unprecedented Visibility
Management noted that backlog entering Q3 is up 18% YoY. This is a dramatic acceleration and a forward-looking indicator that demand is not merely pulling forward, but stacking up. Order entry momentum was described as 'broad-based' across all segments, which directly drove the decision to raise full-year guidance.
Medical Segment: The Gap Between Organic and Reported
Medical and Fluid Solutions (MFS) is technically the lagging segment in reported revenue, growing only 5.0% YoY. However, the data reveals a contradiction: organic growth was actually +8%. The culprit is a 4% drag from the previously divested medical contract manufacturing business. While the underlying business is strong, investors must recognize that the top-line reported number will continue to look artificially suppressed until the divestiture fully annualizes.
CapstanAG Adds Precision Ag Firepower
The strategic acquisition of CapstanAG in March 2026 immediately bolsters the Industrial Precision Solutions (IPS) segment. While small (contributing 1% to IPS growth in Q2), it expands Nordson's precision agriculture footprint with mid-tier North American OEMs. This technology-driven acquisition helps offset broader sluggishness in traditional industrial coating markets.
Non-Operational Noise Drags Down GAAP Metrics
A notable red flag in an otherwise stellar quarter is the disparity between GAAP and Non-GAAP earnings. Net Income grew only 4.4% YoY. The gap was caused by a $24M non-cash pension settlement charge to annuitize 30% of U.S. obligations, alongside a $10.4M non-cash loss on minority investments. While adjustments are standard, large below-the-line volatility complicates the clean execution narrative.
Industrial Precision Solutions (IPS) Stable Amid Macro Headwinds
Despite ongoing global macro concerns in traditional industrial markets, IPS delivered a 10% reported revenue increase (+5% organic, +4% currency, +1% acquisition). Management specifically cited stable demand in broader consumer and industrial end markets. The segment's EBITDA margin dipped slightly to 35.3% from 35.6% a year ago, likely due to integration costs of the CapstanAG acquisition and geographic mix, but remains the company's profit anchor.
Other KPIs
Stable. Free cash flow for the first six months of fiscal 2026 was $293.4 million. Conversion remains well above 100%, indicating that the company's aggressive working capital management strategies enacted during the Ascend Strategy implementation are permanent fixtures of the business model.
Accelerating. Up 8% YoY, representing a 32% margin. This matches the company's structural margin targets. The highest margin segment continues to be Medical and Fluid Solutions at 37%, despite the top-line divestiture drag.
Guidance
Decelerating slightly. The midpoint of $775 million implies approximately 4.5% YoY growth, compared to the 8.5% delivered in Q2. This deceleration is likely an artifact of tougher year-over-year comparables rather than underlying demand destruction, given the 18% surge in backlog.
Accelerating. The midpoint of $3.05 implies an 11.7% YoY growth rate from Q3 2025's $2.73. This highlights continued expected margin expansion and operating leverage.
Accelerating. Raised from the prior quarter's expectation of $2,860 - $2,980 million. The new midpoint ($2,970M) implies roughly 4.7% YoY growth against FY25, indicating strong conviction in the second half of the year.
Accelerating. Raised from the prior quarter's range of $11.00 - $11.60. The new midpoint ($11.55) implies an impressive 12.8% YoY growth over FY25's $10.24. This signals that management expects to easily surpass their long-term double-digit EPS growth targets this year.
Key Questions
Backlog Composition and Lead Times
Backlog is up an impressive 18% year-over-year. How much of this is driven by longer-term scheduled delivery dates for large ATS systems versus near-term core industrial orders, and how have average lead times shifted across the three segments?
Minority Investment Volatility
With a $10.4 million non-cash loss on minority investments this quarter following a $22 million gain last quarter, can you frame the total remaining exposure to these mark-to-market technology investments to help model future below-the-line volatility?
CapstanAG Synergy Timeline
With CapstanAG now closed, how quickly do you expect to integrate these precision agriculture offerings into your existing global sales channels, and when will the acquisition become accretive to IPS segment margins?